Prevalence of HIV Transmitted Drug Resistance in Nanjing from 2018 to 2021
Yifan Su,Mingxue Qi,Mingli Zhong,Nawei Yu,Chen Chen,Zi Ye,Cong Cheng,Zhiliang Hu,Hongying Zhang,Hongxia Wei
DOI: https://doi.org/10.2147/IDR.S391296
2023-02-03
Infection and Drug Resistance
Abstract:Yifan Su, 1 Mingxue Qi, 1 Mingli Zhong, 2 Nawei Yu, 1 Chen Chen, 1 Zi Ye, 1 Cong Cheng, 1 Zhiliang Hu, 1 Hongying Zhang, 3 Hongxia Wei 1 1 Department of Infectious Disease, The Second Hospital of Nanjing Affiliated to Nanjing University of Chinese Medicine, Nanjing, People's Republic of China; 2 Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China; 3 Nanjing Center for Disease Control and Prevention Affiliated with Nanjing Medical University, Nanjing, People's Republic of China Correspondence: Hongxia Wei, Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, 210003, People's Republic of China, Email Hongying Zhang, Email Background: Transmitted drug resistance (TDR) is a major challenge in the clinical management of acquired immunodeficiency syndrome (AIDS). Therefore, this study aimed to investigate the epidemic characteristics of and risk factors for human immunodeficiency virus (HIV)-1 TDR in Nanjing from 2018 to 2021 to provide support for clinical management. Methods: The HIV-1 Pol gene was amplified by nested reverse transcription polymerase chain reaction from venous blood of 1190 HIV-infected patients who did not receive antiviral therapy, and the amplified product was sequenced using an in-house sequencing method. The sequencing result was compared with the HIV drug resistance database from Stanford University to elucidate the rates of antiviral drug resistance and distribution of drug-resistant mutation sites. Factors associated with TDR were evaluated using a logistic regression model. Results: Detection of drug resistance at the gene level was successful in 1138 of 1190 HIV-1-infected patients (95.6%), and the overall 4-year drug resistance rate was 8.2% (93/1138). The drug resistance rate was higher for non-nucleoside reverse transcriptase inhibitors (NNRTIs; 6.7%) than for nucleoside reverse transcriptase inhibitors (NRTIs; 2.5%) or protease inhibitors (PIs; 0.1%) ( χ 2 = 83.907, P< 0.0001). The most common NNRTI-related mutation was V179D/E followed by K103N. M184V was the dominant NRTI-associated mutation, and M46L/I was the most prevalent PI-associated mutation. A CD4 + T cell count of < 50 cells/μL was significantly associated with an increased risk of TDR (OR=3.62, 95% CI: 1.38– 9.51, P=0.009). Conclusion: The prevalence of TDR in the city of Nanjing from 2018 to 2021 was at a moderate epidemic risk according to World Health Organization standards. Continuous monitoring of TDR can inform clinical diagnosis and treatment. Patients with advanced disease and a low CD4 + T lymphocyte count are more likely to have TDR in Nanjing. Keywords: HIV-1, transmitted drug resistance, mutation sites Since the first case of acquired immunodeficiency syndrome (AIDS) was discovered in the United States in 1981, AIDS has spread around the world and become a serious public health concern. The Joint United Nations Program on HIV/AIDS (UNAIDS) estimated that there were 38.4 million people were living with HIV, 1.5 million new cases, and about 650,000 deaths from HIV-related diseases in 2021. 1 Presently, antiretroviral therapy (ART) is the main method of treatment for AIDS. The preferred regimen is two nucleoside reverse transcriptase inhibitors (NRTIs) plus one non-nucleoside reverse transcriptase inhibitor (NNRTI)/protease inhibitor (PI)/integrase inhibitor (INSTI). 2 The recommended regimens in China were tenofovir plus lamivudine or emtricitabine as NRTIs, efavirenz or ripiverin as NNRTIs, ripiverin/ritonavir as PIs and dolutegravir or raltegravir as INSTIs. 2 The National Free Antiretroviral Treatment Program (NFATP) was launched in six provinces in central China in 2003 and subsequently expanded to 31 provinces and autonomous regions in 2006, improving the access of patients living with HIV to antiretroviral treatment. 3,4 Previous research showed that the use of ART in China reduced AIDS-related deaths from 39.3% in 2002 to 14.2% in 2009. 5 However, the continuous use of ART in China has led to an increase in the drug resistance rate in newly-treated patients living with HIV, 6 especially the resistance to NNRTIs. 7 A nationwide cross-sectional survey conducted in 2015 found that the average prevalence of transmitted drug resistance (TDR) was 3.7%, 8 and a significant increase in TDR in different regions was reported by other studies during subsequent years. 9,10 The presence of drug resistance in patients before tr -Abstract Truncated-
pharmacology & pharmacy,infectious diseases